Preclinical studies showed that different sensitivity of BRAF V600E inhibition in melanoma and CRC may be due to the robust adaptive feedback signaling networks harbored in CRC, which leads to the reactivation of MAPK signaling following treatment with a BRAF inhibitor. This evidence concerns the gene BRAF and melanoma.